Context Therapeutics Inc. (NASDAQ:CNTX) Insider Acquires $11,600.00 in Stock

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) insider Alex C. Levit purchased 20,000 shares of the stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $0.58 per share, with a total value of $11,600.00. Following the completion of the acquisition, the insider now directly owns 29,000 shares of the company's stock, valued at approximately $16,820. This represents a 222.22% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Context Therapeutics Stock Down 3.6%

Shares of NASDAQ:CNTX traded down $0.02 during mid-day trading on Friday, reaching $0.63. 170,618 shares of the stock were exchanged, compared to its average volume of 302,288. The company has a market cap of $56.46 million, a P/E ratio of -0.69 and a beta of 1.86. Context Therapeutics Inc. has a one year low of $0.49 and a one year high of $2.75. The stock's 50 day simple moving average is $0.75 and its 200-day simple moving average is $0.91.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). Analysts anticipate that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on CNTX. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. D. Boral Capital reiterated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, May 8th. Finally, William Blair reiterated an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Context Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC bought a new position in Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC bought a new position in Context Therapeutics in the fourth quarter valued at approximately $52,000. Landscape Capital Management L.L.C. bought a new position in Context Therapeutics in the fourth quarter valued at approximately $94,000. Finally, Walleye Capital LLC grew its stake in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after purchasing an additional 56,651 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.